Comparison of Efficacy and Tolerability of APD Treatment With Different PD Cyclers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-05-31

Study Completion Date

2021-10-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study has been designed in order to investigate the performance and safety of the new Silencia PD cycler including the Silencia tubing system in comparison to the PD-Night and Homechoice PD cycler which are both well-established PD cyclers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Tolerability of the APD Treatment in PAED Patients

NCT07004907

Renal Failure Acute Chronic

NOT_YET_RECRUITING NA

Renal Denervation in End Stage Renal Disease Patients With Refractory Hypertension

NCT00753116

Kidney Failure, Chronic Renal Dialysis

COMPLETED PHASE1

PD-Improved Dialysis Efficiency With Adapted APD

NCT02470598

Chronic Renal Failure

COMPLETED

Comparison of Clinical Performance and Hemocompatibility of Dialyzers Applied During Post-dilution Online Hemodiafiltration

NCT04714281

Renal Failure End Stage Renal Disease

COMPLETED NA

Renal Denervation in Patients With Chronic Heart Failure & Renal Impairment Clinical Trial

NCT01392196

Heart Failure

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Failure End Stage Renal Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SEQUENTIAL

Prospective, controlled, multicentre, interventional

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Peritoneal dialysis PD

Treatment for 2 weeks either with the comparators PD-Night or Homechoice PD cycler depending on the previous treatment (clinical phase I). At the end of these 2 treatment weeks and a subsequent training phase which up to 3 weeks, treatment with the Silencia PD cycler for 2 further weeks (clinical phase II).

Group Type EXPERIMENTAL

PD cycler Silencia

Intervention Type DEVICE

Treatment for 2 weeks either with PD-Night or Homechoice PD cycler (Comparators) depending on the previous Treatment ((clinical phase I). At the end of these 2 treatment weeks and a subsequent training phase which up to 3 weeks, treatment with the Silencia PD cycler for 2 further weeks (clinical phase II).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PD cycler Silencia

Treatment for 2 weeks either with PD-Night or Homechoice PD cycler (Comparators) depending on the previous Treatment ((clinical phase I). At the end of these 2 treatment weeks and a subsequent training phase which up to 3 weeks, treatment with the Silencia PD cycler for 2 further weeks (clinical phase II).

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Informed consent signed and dated by study patient and investigator/authorised physician
* CKD patients being treated with APD for at least 3 months
* Minimum age of 18 years
* Body weight ≥ 40 kg
* Fluid status regularly monitored with Body Composition Monitor (BCM)
* Patients planned to change to the Silencia PD cycler
* Proper functioning catheter
* Intraperitoneal Pressure (IPP) ≤ 18 cm H2O for the maximum of TAVO parameter "permitted patient volume"
* Ability to understand the nature and requirements of the study

Exclusion Criteria

* Patients who have any condition prohibiting the use of BCM, like patients with major amputations (e.g. lower leg)
* Patients receiving polyglucose containing PD solution
* Any conditions which could interfere with the patient's ability to comply with the study
* Patients who suffer from peritonitis/exit site infection during the last 4 weeks
* Women of childbearing age without effective means of contraception, pregnancy (pregnancy test will be conducted at start and end of study) or lactation period
* Life expectancy \< 3 months
* Participation in an interventional clinical study during the preceding 30 days
* Previous participation in the same study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No